5-Azacytidine and DLI can induce long-term remissions in AML patients relapsed after allograft

Azacitidine salvage therapy for relapse of myeloid malignancies following allogeneic hematopoietic SCT

(2014) B Tessoulin et al.   BONE MARROW TRANSPLANTATION

Low dose decitabine in very high risk relapsed or refractory acute myeloid leukaemia in children and young adults

(2013) Christine L. Phillips et al.   BRITISH JOURNAL OF HAEMATOLOGY

Salvage therapy with azacitidine increases regulatory T cells in peripheral blood of patients with AML or MDS and early relapse after allogeneic blood stem cell transplantation

(2013) T Schroeder et al.   LEUKEMIA

Azacitidine and donor lymphocyte infusions as first salvage therapy for relapse of AML or MDS after allogeneic stem cell transplantation

(2013) T Schroeder et al.   LEUKEMIA

Expression of PD-L1, PD-L2, PD-1 and CTLA4 in myelodysplastic syndromes is enhanced by treatment with hypomethylating agents

(2013) H Yang et al.   LEUKEMIA

P-242 Decitabine treatment induces NY-ESO1 promoter hypomethylation, Transcription and protein expression in circulating AML blasts

(2013) E.A. Griffiths et al.   LEUKEMIA RESEARCH

Azacitidine augments expansion of regulatory T cells after allogeneic stem cell transplantation in patients with acute myeloid leukemia (AML)

(2012) O. C. Goodyear et al.   BLOOD

Multicenter, Randomized, Open-Label, Phase III Trial of Decitabine Versus Patient Choice, With Physician Advice, of Either Supportive Care or Low-Dose Cytarabine for the Treatment of Older Patients With Newly Diagnosed Acute Myeloid Leukemia

(2012) Hagop M. Kantarjian et al.   JOURNAL OF CLINICAL ONCOLOGY

Low-Dose Decitabine Versus Best Supportive Care in Elderly Patients With Intermediate- or High-Risk Myelodysplastic Syndrome (MDS) Ineligible for Intensive Chemotherapy: Final Results of the Randomized Phase III Study of the European Organisation for Research and Treatment of Cancer Leukemia Group and the German MDS Study Group

(2011) Michael Lübbert et al.   JOURNAL OF CLINICAL ONCOLOGY

Azacitidine for treatment of imminent relapse in MDS or AML patients after allogeneic HSCT: results of the RELAZA trial

(2011) U Platzbecker et al.   LEUKEMIA

Induction of a CD8+ T-cell response to the MAGE cancer testis antigen by combined treatment with azacitidine and sodium valproate in patients with acute myeloid leukemia and myelodysplasia

(2010) O. Goodyear et al.   BLOOD

Maintenance therapy with low-dose azacitidine after allogeneic hematopoietic stem cell transplantation for recurrent acute myelogenous leukemia or myelodysplastic syndrome

(2010) Marcos de Lima et al.   CANCER

The DNA demethylating agent 5-aza-2′-deoxycytidine induces expression of NY-ESO-1 and other cancer/testis antigens in myeloid leukemia cells

(2010) Maika Almstedt et al.   LEUKEMIA RESEARCH

Immunomodulatory effect of 5-azacytidine (5-azaC): potential role in the transplantation setting

(2009) L. I. Sanchez-Abarca et al.   BLOOD

5-Azacytidine for the treatment of patients with acute myeloid leukemia or myelodysplastic syndrome who relapse after allo-SCT: a retrospective analysis

(2009) A Czibere et al.   BONE MARROW TRANSPLANTATION

Non-intensive treatment with low-dose 5-aza-2′-deoxycytidine (DAC) prior to allogeneic blood SCT of older MDS/AML patients

(2009) M Lübbert et al.   BONE MARROW TRANSPLANTATION

Efficacy of a 3-day, low-dose treatment with 5-azacytidine followed by donor lymphocyte infusions in older patients with acute myeloid leukemia or chronic myelomonocytic leukemia relapsed after allografting

(2009) M Lübbert et al.   BONE MARROW TRANSPLANTATION

Low-dose azacitidine after allogeneic stem cell transplantation for acute leukemia

(2009) Elias Jabbour et al.   CANCER

Efficacy of azacitidine compared with that of conventional care regimens in the treatment of higher-risk myelodysplastic syndromes: a randomised, open-label, phase III study

(2009) Pierre Fenaux et al.   LANCET ONCOLOGY

Monosomal Karyotype in Acute Myeloid Leukemia: A Better Indicator of Poor Prognosis Than a Complex Karyotype

(2008) Dimitri A. Breems et al.   JOURNAL OF CLINICAL ONCOLOGY